Addition of vandetanib to chemotherapy in advanced solid cancers: A meta-analysis

Anti-Cancer Drugs

Volumn 23, Issue 7, 2012, Pages 731-738

  Wu, Xiaomin ^a   Jin, Yan ^a,b   Cui, Isabelle H ^c   Xu, Zhi ^a   Zhang, Yangmei ^a   Zhang, Xiaojing ^a   Tang, Cuiju ^a   Gong, Yongling ^a   Chen, Jinfei ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

advanced solid cancers; meta analysis; target therapy; vandetanib

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; PACLITAXEL; PEMETREXED; PLACEBO; PREDNISOLONE; VANDETANIB;

ADENOCARCINOMA; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; META ANALYSIS; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; RISK; SMOKING; THYROID CANCER;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; HUMANS; LUNG NEOPLASMS; NEOPLASMS; PIPERIDINES; QUINAZOLINES; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 84863601182     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32835514f4     Document Type: Article

References (33)

1. Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002; 62:7284-7290. (Pubitemid 36025251)
2. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002; 62:4645-4655.
3. Santoro M, Melillo RM, Carlomagno F, Vecchio G, Fusco A. Minireview: ret: Normal and abnormal functions. Endocrinology 2004; 145:5448-5451. (Pubitemid 39564582)
4. Naumov GN, Nilsson MB, Cascone T, Briggs A, Straume O, Akslen LA, et al. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res 2009; 15:3484-3494.
5. Holden SN, Eckhardt SG, Basser R, de Boer R, Rischin D, Green M, et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 2005; 16:1391-1397. (Pubitemid 41158486)
6. Tamura T, Minami H, Yamada Y, Yamamoto N, Shimoyama T, Murakami H, et al. A phase I dose-Escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thorac Oncol 2006; 1:1002-1009. (Pubitemid 47181370)
7. Qi WX, Tang LN, He AN, Shen Z, Yao Y. The role of vandetanib in the second-Line treatment for advanced non-Small-Cell-Lung cancer: A meta-Analysis of four randomized controlled trials. Lung 2011; 189: 437-443.
8. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996; 17:1-12. (Pubitemid 26120810)
9. Hsu C, Yang TS, Huo TI, Hsieh RK, Yu CW, Hwang WS, et al. Vandetanib in patients with inoperable hepatocellular carcinoma: A phase II, randomized, double-Blind, placebo-Controlled study. J Hepatol 2012; 56:1097-1103.
10. Choueiri TK, Ross RW, Jacobus S, Vaishampayan U, Yu EY, Quinn DI, et al. Double-Blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-Pretreated metastatic urothelial cancer. J Clin Oncol 2012; 30:507-512.
11. Natale RB, Thongprasert S, Greco FA, Thomas M, Tsai C-m, Sunpaweravong P, et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-Small-Cell lung cancer. J Clin Oncol 2011; 29:1059-1066.
12. Natale RB, Bodkin D, Govindan R, Sleckman BG, Rizvi NA, Capo A, et al. Vandetanib versus gefitinib in patients with advanced non-Small-Cell lung cancer: Results from a two-Part, double-Blind, randomized phase ii study. J Clin Oncol 2009; 27:2523-2529.
13. Horti J, Widmark A, Stenzl A, Federico MH, Abratt RP, Sanders N, et al. A randomized, double-Blind, placebo-Controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-Refractory prostate cancer. Cancer Biother Radiopharm 2009; 24:175-180.
14. Heymach JV, Paz-Ares L, De Braud F, Sebastian M, Stewart DJ, Eberhardt WEE, et al. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-Line treatment for advanced non-Small-Cell lung cancer. J Clin Oncol 2008; 26:5407-5415.
15. Heymach JV, Johnson BE, Prager D, Csada E, Roubec J, Pesek M, et al. Randomized, placebo-Controlled phase II study of vandetanib plus docetaxel in previously treated non small-Cell lung cancer. J Clin Oncol 2007; 25:4270-4277. (Pubitemid 47548567)
16. Herbst RS, Sun Y, Eberhardt WEE, Germonpre P, Saijo N, Zhou C, et al. Vandetanib plus docetaxel versus docetaxel as second-Line treatment for patients with advanced non-Small-Cell lung cancer (ZODIAC): A doubleblind, randomised, phase 3 trial. Lancet Oncol 2010; 11:619-626.
17. Arnold AM, Seymour L, Smylie M, Ding K, Ung Y, Findlay B, et al. Phase II study of vandetanib or placebo in small-Cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: NATIONAL Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol 2007; 25:4278-4284. (Pubitemid 47548568)
18. De Boer RH, Arrieta O, Yang CH, Gottfried M, Chan V, Raats J, et al. Vandetanib plus pemetrexed for the second-Line treatment of advanced non-Small-Cell lung cancer: A randomized, double-Blind phase III trial. J Clin Oncol 2011; 29:1067-1074.
19. Yang TS, Oh DY, Guimbaud R, Szanto J, Salek T, Thurzo L, et al. Vandetanib plus mFOLFOX6 in patients with advanced colorectal cancer (CRC): A randomized, double-Blind, placebo-Controlled phase II study [abstract]. J Clin Oncol 2009; 27 (suppl):4084.
20. Lee J, Hirsh V, Park K, Qin S, Blajman CR, Perng R, et al. Vandetanib versus placebo in patients with advanced non-Small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): A randomized, double-Blind phase III trial (ZEPHYR) [abstract]. J Clin Oncol 2010; 28 (suppl):7525.
21. Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: A randomized, double-Blind phase III trial. J Clin Oncol 2012; 30:134-141.
22. Leboulleux S, Bastholt L, Krause TM, De La Fouchardiere C, Tennvall J, Awada A, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer (papillary or follicular; DTC): A randomized, double-Blind phase II trial [abstract]. Ann Oncol 2010; 21 (Suppl. viii):viii 315.
23. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-Small-Cell lung cancer. N Engl J Med 2005; 353:123-132. (Pubitemid 41058344)
24. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, et al. Gefitinib versus docetaxel in previously treated non-Small-Cell lung cancer (INTEREST): A randomised phase III trial. Lancet 2008; 372:1809-1818.
25. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-Institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-Small-Cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003; 21:2237-2246. (Pubitemid 46621858)
26. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-Small cell lung cancer: A randomized trial. JAMA 2003; 290:2149-2158. (Pubitemid 37432975)
27. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-Carboplatin alone or with bevacizumab for non-Small-Cell lung cancer. N Engl J Med 2006; 355:2542-2550. (Pubitemid 44917502)
28. Hirsch FR, Kabbinavar F, Eisen T, Martins R, Schnell FM, Dziadziuszko R, et al. A randomized, phase II, biomarker-Selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-Line therapy for advanced non-Small-Cell lung cancer. J Clin Oncol 2011; 29:3567-3573.
29. Inoue A, Kobayashi K, Usui K, Maemondo M, Okinaga S, Mikami I, et al. First-Line gefitinib for patients with advanced non-Small-Cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 2009; 27:1394-1400.
30. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczesna A, Juhasz E, et al. Erlotinib as maintenance treatment in advanced non-Small-Cell lung cancer: A multicentre, randomised, placebo-Controlled phase 3 study. Lancet Oncol 2010; 11:521-529.
31. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009; 361:958-967.
32. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-Small-Cell lung cancer with mutated EGFR. N Engl J Med 2010; 362:2380-2388.
33. Shibuya K, Komaki R, Shintani T, Itasaka S, Ryan A, Jurgensmeier JM, et al. Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-Small-Cell lung cancer. Int J Radiat Oncol Biol Phys 2007; 69: 1534-1543. (Pubitemid 350116420)